Tirzepatide Peptide

What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained

The short version

What is tirzepatide? At its simplest: a man-made version of two gut hormones in one injection. The human body makes two natural hormones called GIP and GLP-1 that are released from the gut after eating and tell the pancreas to make insulin. Tirzepatide is a synthetic peptide — a short protein — designed to activate both of those hormone receptors simultaneously, something no approved drug had done before.

It is FDA-approved as a prescription medicine — first for type 2 diabetes in 2022, then for weight management in adults with obesity in 2023, and later for obstructive sleep apnea in adults with obesity. In clinical trials it produced weight losses of up to 20.9% at 72 weeks and reduced blood sugar markers more than any prior approved agent in direct comparisons.

What is tirzepatide — the peptide structure

What is tirzepatide structurally? It is a 39-amino-acid synthetic peptide (molecular formula C225H348N48O68, molecular weight 4,813.53 Da, CAS number 2023788-19-2) built on the native GIP amino-acid backbone [1]. A C20 fatty-diacid (eicosanedioic acid) modification is attached via a glutamic acid linker and two (2-(2-aminoethoxy)ethoxy)acetic acid units to a lysine side chain mid-sequence — this fatty-diacid arm binds to serum albumin in the bloodstream, dramatically slowing clearance and extending the half-life to approximately five days, enabling once-weekly dosing [1].

The drug class is dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — in plainer terms, a dual incretin mimetic. The synonyms 'twincretin' and 'dual incretin mimetic' both describe the same thing: a single molecule that copies two natural incretin hormones simultaneously [1][2].

The ATC classification code is A10BX16 (blood-glucose-lowering drugs, other). Eli Lilly developed it under the code LY3298176 before the INN 'tirzepatide' was assigned [1].

What is tirzepatide used for — approved indications

Tirzepatide is FDA-approved for three indications [11][12][41]:

  1. Type 2 diabetes mellitus — approved May 2022 as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. The SURPASS programme established the glycaemic efficacy: in SURPASS-2, tirzepatide at 15 mg reduced HbA1c by 2.30 percentage points versus 1.86 pp with semaglutide 1 mg over 40 weeks [3].
  1. Chronic weight management — approved November 2023 for adults with a BMI of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related complication (e.g., type 2 diabetes, hypertension, dyslipidaemia), as an adjunct to a reduced-calorie diet and increased physical activity. The SURMOUNT-1 trial produced mean weight change of -20.9% at 15 mg versus -3.1% with placebo over 72 weeks [5].
  1. Obstructive sleep apnea — approved for moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA trial showing a 25.3 event/hour reduction in apnea-hypopnea index (the standard measure of OSA severity) versus roughly 5 events/hour with placebo [13].

Timeline: the compound was first described in 2018, the phase 3 SURPASS programme reported 2021–2022, the SURMOUNT programme 2022–2025. It is not approved for type 1 diabetes, and the weight-loss indication is not available as an off-label extension of the diabetes label — the obesity indication has its own regulatory basis [22].

Is tirzepatide a GLP-1? The receptor-class distinction

Is tirzepatide a GLP-1? Not exactly — and the distinction matters. A selective GLP-1 receptor agonist (GLP-1 RA) activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor AND the GIP receptor — it is a dual GIP/GLP-1 receptor agonist, sometimes called a GLP-1/GIP dual agonist or dual incretin receptor agonist [2].

This dual-receptor engagement is the defining pharmacological feature. In the 2020 characterisation by Willard et al. (JCI Insight), tirzepatide was shown to be an imbalanced dual agonist — it engages the GIP receptor to a greater degree than the GLP-1 receptor — and to exhibit biased GLP-1R signalling favouring cAMP generation over beta-arrestin recruitment [2]. The GIPR arm contributes additional effects, particularly in adipose tissue (nutrient buffering and lipid clearance) and potentially in the CNS (appetite suppression with attenuation of nausea), that GLP-1R agonism alone does not provide [8][40].

The clinical consequence: tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg in SURPASS-2 [3] and greater body weight reduction than maximum-tolerated semaglutide in SURMOUNT-5 [6].

Is tirzepatide a peptide?

Yes. Tirzepatide is a synthetic peptide — a peptide being a chain of amino acids shorter than a protein, in this case 39 amino acids. It is in the same chemical class as the natural incretin hormones it mimics (GIP is 42 amino acids; GLP-1 is 30 amino acids in its active form) but is not a copy of either — it is a novel synthetic sequence built on the GIP backbone with structural modifications that enable dual-receptor engagement and long duration of action [1][2].

The peptide classification also means tirzepatide must be injected rather than swallowed in its current approved form — peptides are broken down in the gut by digestive enzymes before they can be absorbed. Subcutaneous injection delivers it directly into the tissue beneath the skin, from which it is absorbed into the bloodstream and binds albumin via its fatty-diacid arm [1][21].